Well in a way you are correct, although some posters spend huge amounts of time talking about numbers of people in the US infected with Covid...
But anyway Novartis is actually interested in a treatment for "all cause ARDS", for which "Covid ARDS" was to be the investigative model. So following your line of thought that Covid itself is not relevant, then so also is any requirement for the FDA to approve Remestemcel as a Covid treatment.
The critical point is whether or not Novartis discerned any efficacy in the treatment of ARDS from the trial, but since the trial was stopped early for futility and Novartis haven't ratified the agreement they made with MSB, you would have to conclude an efficacy signal is not very strong.
New Covid 19 treatment, page-273
-
- There are more pages in this discussion • 172 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |